The AI Buildout Needs These 10 Stocks

You don’t have to buy OpenAI or Anthropic to invest in AI. Each large language model requires specialized technology to keep running and growing.

MarketBeat’s The Infrastructure’s Backbone: 10 Stocks Powering the AI Buildout report reveals 10 companies supplying the memory, storage, connectivity, fabrication, power, and cooling behind AI’s next phase.

Proof season in a narrowing tape

The tape is getting healthier, but participation is thin and the market is paying for proof. This issue leans into margins and operating data that can still reset narratives as earnings bunch up.

Today’s market read

The backdrop is improving, but stock selection still matters.

01 Market Direction

Improving. The short-term trend is getting healthier, but not everything is confirmed.

02 Market Participation

Fading. Fewer stocks are helping.

03 Strongest Sector

Healthcare. Investors are showing the most interest here right now.

RPM heads into Q4 with margins as the swing factor

Key points

  • Shares rose 5.8 percent to 107.43, still about 17 percent below the 52-week high.

  • Street sits near 1.83 in earnings per share on roughly 2.2 billion of revenue. Margin direction is the lever.

  • Focus on gross margin, segment mix, and backlog conversion at current pricing.

  • Group breadth is weak. Margin progress could pop, but softer price or volume may swamp it.

With RPM International fiscal fourth-quarter earnings on deck, the setup is about price over cost more than headline revenue. Shares jumped 5.8 percent to 107.43 into the print yet remain roughly a sixth below the high, which resets expectations toward proof that pricing discipline and easing inputs can widen the spread.

Evidence that matters next is straightforward. A higher gross margin line with stable price mix, cleaner segment contribution, and a backlog that converts on schedule at current pricing would tell you the reset is working. In coatings, that combination can change the read even if revenue looks flat.

The risk is on both sides of the spread. If volumes or pricing soften while feedstocks do not cooperate, a modest beat can get muted by weak chemicals breadth. Conversely, if incremental margins lift while volumes stabilize, a flat-looking quarter can still be reframed as improving quality of earnings.

Watch the cadence management gives on cost relief timing and any commentary on specialty versus consumer mix. A clearer runway for price realization into the back half would be the tell that this is more than a one-quarter bounce.

Hotel REITs are leading, but earnings must validate

Key points

  • XLRE shows July net inflows with shares outstanding near 190 million.

  • RLJ, Pebblebrook, and Xenia hit one-year highs with strong three-month gains.

  • RevPAR, occupancy, and property-level costs are the earnings hinge.

  • Fading flows or margin pressure would blunt any Real Estate rotation.

Flows and price are aligned for now. XLRE has July net inflows and shares outstanding near 190 million as RLJ Lodging Trust, Pebblebrook Hotel Trust, and Xenia Hotels &amp, Resorts print fresh highs. That makes the test simple as we enter the hotel REIT earnings window.

What matters is whether revenue per available room and occupancy are firm enough to lift margins without expenses taking the benefit. Mix between business and leisure, plus any rate power in urban and resort markets, will decide if stronger tape turns into stronger profit dollars.

Risks are visible. If flows fade or property-level costs pinch room gains, the group can give back leadership quickly. These are rate-sensitive balance sheets, so any shift in rate expectations around the prints can amplify moves.

Timing is tight. Pebblebrook reports July 29, Xenia follows July 30, and RLJ is set for August 6. A clean set of receipts there would confirm whether hotels are pulling a broader Real Estate turn or just catching a tailwind.

Chemicals split ahead of a tight late-July print cycle

Key points

  • One-month returns are weak, but sub-industries are separating into prints.

  • Huntsman on July 31 is the diversified check on volumes and pricing discipline.

  • Tronox on August 6 is the titanium dioxide price and reorder read.

  • ASP Isotopes on August 14 is a small-cap demand and cash runway signal.

Chemicals have slipped on rotation work, and the pullbacks are sharp in spots. Tronox is down about 22.9 percent in a month, ASP Isotopes is off roughly 41.9 percent, and Huntsman has eased near 7.4 percent. That frames Huntsman, Tronox, and ASP Isotopes into late-July earnings as the instrument panel for the group.

For Huntsman, a sequential volume uptick with at least flat selling prices and some incremental margin lift would say normalization is progressing. Tronox is the titanium dioxide check. Better order rates with stable contract pricing would argue the weakness is more localized than systemic.

ASP Isotopes is the small-cap tell. Demand posture and any clarity on cash runway will color risk tolerance across niche chemical names. After sharp one-month moves, guidance tone can matter as much as the print itself.

Across the cluster, watch the prices, volumes, inventories, and how management frames the back half. If even two of the three clear those marks, the market can keep sorting within chemicals rather than broadening the slide.

Into next week, the strongest sector on our board is Healthcare, but the near-term action likely pivots on margin signals from coatings, hotel receipts, and the chemicals instrument panel. We will stay focused on where the data confirm the turn.